The Tablet Characterization with Regulatory Compliance Methods

Many global pharmaceutical companies are often faced with a volume of content in the field that has grown to a point where the quality of that labeling is unknown. Assessment of what exists and correcting the process to avoid pitfalls in the future can be a daunting task.

In this webcast, experts will discuss the current status and assess the potential market impact for the pharmaceutical industry. The discussion will review the current legal situation and the position of the different regulatory bodies. Participants will learn about the science-based facts influencing the industry response and gain insight into the possible implications on the use of TiO2 in pharmaceutical products, as well as food supplements.

Gain a better understanding of quality health care and improved patient outcomes based on the quality of care. Health care is quickly becoming a commodity. The increased focus on quality by CMS and other payer sources has driven the need to create effective strategies to control costs. One such strategy is reducing preventable readmissions. Hospitals are keenly aware of the cost of readmissions, both in penalties from CMS and in their reputation as centers for quality and improved patient outcomes. The purpose of this information is to equip the user with the tools to identify those patients at risk, to intervene when necessary, to disseminate to their staff, and to ensure that lasting change will occur. This information is an intermediate level course designed for mid to upper-level hospital administrators. This course is ideal for the hands-on manager to assess and implement a hospital-wide program aimed at reducing the number of readmissions.

When it comes to medical product discovery, development, and delivery, patients need to be front and center but how close (or far away) are we from truly having a system that routinely measures what matters to patients? A panel of industry, regulatory, and patient leaders will discuss what’s next for patient-centered measurement. Panelists will define patient-centered measurement; identify novel strategies for capturing patient-centered outcomes; assess the progress in product development, regulatory approval, and delivery; and address how to advance the science of patient input in a way that fulfills the unmet needs of patients across diseases.